Skip to content

An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes

An Integrated Care Model for Improving HCV Patient Outcomes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00722423
Acronym
HCV
Enrollment
364
Registered
2008-07-25
Start date
2009-05-31
Completion date
2014-05-31
Last updated
2015-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Keywords

Hepatitis C, integrated care, alpha interferon, mental health

Brief summary

This is a prospective randomized controlled trial comparing two different clinic models for patients with hepatitis C. These patients commonly have mental health problems that are barriers to receiving HCV treatment. Patients giving informed consent will be randomized to a usual care HCV clinic vs. a HCV clinic with the addition of an on-site mental health practitioner who will address psychiatric and substance use issues with the goal of enabling patients to undergo effective antiviral therapy. The major outcome of the study is the number of patients in each group who are cured with antiviral therapy. Patients in both groups receive current standard of care.

Detailed description

Impact for Veterans: Treatments are available that can often eliminate the hepatitis C virus (HCV) in infected veterans, resulting in increased life expectancy and quality of life. However, many veterans do not get treated or fail treatment because of a variety of factors. Using a new protocol-based model of care that centers around integrating psychiatric care and case management into VA HCV clinics, it may be possible to increase treatment rates, improve rates of sustained viral response (SVR), and improve health outcomes for veterans with hepatitis C. Background: The prevalence of hepatitis C virus (HCV) infection among VA patients is 3x higher than in the general population. VA patients with HCV have characteristics linked to increased risk for progression to cirrhosis, such as male sex, high body mass index, tobacco or marijuana use, and a history of heavy alcohol use. Antiviral treatment is the only evidence-based treatment that has been shown to eradicate the HCV virus and reduce the progression of liver fibrosis. However, recent VA data indicate that only about 14% of all HCV-infected VA patients have ever received antiviral therapy. Barriers to receiving antiviral treatment include factors such as pre-existing psychiatric illness, ongoing substance abuse, and other medical co-morbidity. Patients with psychiatric and substance use histories have benefitted from an integrated care approach to HCV care, but a more rigorous study design is required to demonstrate effectiveness. Primary Objective: To determine the effectiveness of a protocol-based integrated care model for increasing treatment rates and the number of patients with successful antiviral treatment as measured by an increase in percentage of all new HCV patients achieving a sustained virologic response (SVR). We hypothesize that this model will increase the proportion of patients who are fully evaluated for treatment, who initiate treatment, and who complete treatment compared with patients that receive usual care. Secondary Objectives: Assess the effects of an integrated care model on patient involvement in care (appointment attendance) and PROs (substance abuse, depression, anxiety). We hypothesize that veterans managed with the integrated care model will have better attendance at HCV clinic appointments, have improved rates of drug and alcohol abstinence, and fewer psychological symptoms. Project Methods: The intervention is an integrated clinical care model developed and initially studied at the Minneapolis VA HCV Clinic. The preliminary study found that integrated care resulted in higher treatment rates, higher SVRs, reduced substance use, and improved psychological functioning. Thus, we will use a more rigorous randomized design to study the effectiveness of this intervention at 3 major VA medical centers. All clinic patients will be screened for depression, anxiety, PTSD, or recent SUDs and all patients that screen positive on 1 or more of these measures will be asked to participate. Preliminary data suggest that 85% of HCV clinic patients screen positive on at least one measure. Eligible patients will be randomized to either usual or integrated care at each site. The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals. Clinical data will be obtained from VA medical records by the study coordinator at each site. PROs will be assessed using validated measures. Data will be analyzed using hierarchical linear modeling (HLM) techniques.

Interventions

The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.

Sponsors

US Department of Veterans Affairs
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Chronic hepatitis C. This is defined as the documentation of the presence of circulating hepatitis C virus by a positive hepatitis C Polymerase Chain Reaction test that is compatible with chronic hepatitis. (Note: no requirement is made for the presence of abnormal liver function tests). * Patients may be treatment na ve or have received and failed prior antiviral treatment. * Age 18-75 years. * Patient must be able to give informed consent. * All antiviral treatments are administered according to accept standards of care at each site, with appropriate pre-treatment evaluation and on-treatment management and precautions. Liver biopsies are an accepted standard of care for patients with chronic hepatitis C and are obtained as clinically indicated. * Patients must meet screening criteria for high risk for mental health and substance use problems. High risk HCV patient is defined as a patient with Beck Depression Inventory-II\>10 at screening; active drug use indicated by positive urine screen, self-reported use within 6 months on drug use questionnaire or AUDIT-C test \>4, or positive PTSD screen.

Exclusion criteria

* Patient unable or unwilling to participate. * Decompensated liver disease, with active or recent encephalopathy, variceal bleeding, or ascites or CHILD-PUGH class B or C. (Note: patients with a history of decompensated cirrhosis in the past with resolution who are otherwise antiviral treatment candidates in the opinion of the treating physician will be considered candidates.) * Other significant near term life-threatening diseases (malignancy, unstable angina, severe chronic obstructive pulmonary disease, pulmonary fibrosis, etc.)

Design outcomes

Primary

MeasureTime frameDescription
Sustained Virologic Response Rates12-24 weeks post-treatmentVirus not detected by PCR assay

Secondary

MeasureTime frameDescription
Antiviral Treatment Rate12-24 weeks post-treatmentNumber of patients started antiviral treatment

Countries

United States

Participant flow

Participants by arm

ArmCount
Integrated Care Model
Integrated care model: The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
182
Usucal Care Model181
Total363

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyProtocol Violation01

Baseline characteristics

CharacteristicIntegrated Care ModelUsucal Care ModelTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
182 Participants181 Participants363 Participants
Age, Continuous55.3 years
STANDARD_DEVIATION 5.51
55.5 years
STANDARD_DEVIATION 5.79
55.4 years
STANDARD_DEVIATION 5.65
Ethnicity (NIH/OMB)
Hispanic or Latino
32 Participants33 Participants65 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
69 Participants62 Participants131 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
81 Participants86 Participants167 Participants
Region of Enrollment
United States
182 participants181 participants363 participants
Sex: Female, Male
Female
4 Participants4 Participants8 Participants
Sex: Female, Male
Male
178 Participants177 Participants355 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 00 / 0
serious
Total, serious adverse events
112 / 182125 / 181

Outcome results

Primary

Sustained Virologic Response Rates

Virus not detected by PCR assay

Time frame: 12-24 weeks post-treatment

ArmMeasureValue (NUMBER)
Integrated Care ModelSustained Virologic Response Rates29 participants
Usual Care ModelSustained Virologic Response Rates14 participants
Secondary

Antiviral Treatment Rate

Number of patients started antiviral treatment

Time frame: 12-24 weeks post-treatment

ArmMeasureValue (NUMBER)
Integrated Care ModelAntiviral Treatment Rate31.9 percentage of participants
Usual Care ModelAntiviral Treatment Rate18.8 percentage of participants

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026